Triptorelin market value is predicted to reach USD 1.49 billion by 2032, according to a new research report by Global Market Insights Inc. Rising awareness about precocious puberty is a key driver ...

The global triptorelin market is set for substantial growth, according to the latest market analysis report. Forecasts indicate that the market, valued at approximately USD 955.50 million in 2023, is ...

MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or ...

The Triptorelin Market is expected to be worth around US$ 955.50 million in 2023. Industry is predicted to expand at a 5% CAGR from 2023 to 2033, powered by the rising prevalence of endometriosis ...

Dec 5 (Reuters) - Luye Pharma Group Ltd: * TRIPTORELIN ACETATE EXTENDED-RELEASE MICROSPHERES FOR INJECTION (LY01007) COMPLETED PHASE I CLINICAL TRIAL IN CHINA Source text for Eikon: Further company ...

Triptorelin 6-month formulation phase III trial demonstrates good efficacy in terms of pituitary and gonadal suppression and in arresting or reversing progression of clinical signs of puberty and ...

Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs and companion diagnostics ...